Premium
High growth fraction at 9 grays of radiotherapy is associated with a good prognosis for patients with cervical squamous cell carcinoma
Author(s) -
Oka Kuniyuki,
Suzuki Yoshiyuki,
Nakano Takashi
Publication year - 2000
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(20001001)89:7<1526::aid-cncr16>3.0.co;2-2
Subject(s) - medicine , radiation therapy , cervical cancer , ki 67 , biopsy , pathology , population , immunohistochemistry , cancer , oncology , gastroenterology , environmental health
BACKGROUND MIB‐1, a murine monoclonal antibody, recognizes the Ki‐67 antigen of routinely processed paraffin sections after microwave treatment. Cycling cells are positive for MIB‐1 in their nucleus, and quiescent cells are negative for MIB‐1. The MIB‐1 labeling index represents the growth fraction of the cell population. METHODS A total of 150 cervical biopsy specimens were taken from 75 consecutive patients with cervical squamous cell carcinomas before radiotherapy (RT) and at 9 grays (Gy) of RT and were investigated to analyze the correlation between the MIB‐1 labeling index or the δMIB‐1 labeling index and patient prognosis or local disease control. The δMIB‐1 index was calculated as the MIB‐1 index at 9 Gy minus the MIB‐1 index before RT. RESULTS The mean MIB‐1 index was 38% (range, 11–67%) before RT and 54% (range, 15–85%) at 9 Gy. The MIB‐1 index at 9 Gy was related to prognosis, including overall survival ( P = 0.025), disease free survival ( P = 0.024), and metastasis free survival ( P = 0.045). Patients who had a δMIB‐1 index > 20% showed a trend toward a higher disease free survival rate compared with patients who had a δMIB‐1 index < 20% ( P = 0.093). Neither the MIB‐1 index nor the δMIB‐1 index was associated with local disease control. CONCLUSIONS The high growth fraction at 9 Gy is regarded as a predictive factor for a good prognosis in patients with cervical squamous cell carcinoma patients who undergo RT alone. Cancer 2000;89:1526–31. © 2000 American Cancer Society.